SCHEMBL1129551

SCHEMBL1129551

CCCCCCCCCCCCCCCCCCCC(=O)NCCc1c[nH]c2ccc(OC)cc12

nearest known ligand 0.92

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 11/20 0.92
MTNR1B P49286 5/20 0.92
TRPV1 Q8NER1 4/20 0.75
KMT2A Q03164 3/20 0.69
MEN1 O00255 2/20 0.69
KDM4E B2RXH2 1/20 0.69
ALDH1A1 P00352 1/20 0.69
CYP1A1 P04798 1/20 0.69
MPO P05164 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
HTR1A P08908 1/20 0.69
CYP2D6 P10635 1/20 0.69
HPGD P15428 1/20 0.69
NQO2 P16083 1/20 0.69
HTR2B P41595 1/20 0.69
RAB9A P51151 1/20 0.69
BLM P54132 1/20 0.69
PMP22 Q01453 1/20 0.69
CYP1B1 Q16678 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8571512 1.00 MTNR1A (0.92) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL7505689 1.00 MTNR1A (0.92) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL31036086 0.96 MTNR1A (0.87) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL3815621 0.95 MTNR1A (0.83) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL5616635 0.92 MTNR1A (0.85) MTNR1AMTNR1BKMT2AMEN1KDM4E
SCHEMBL1129785 0.92 MTNR1A (0.77) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL14907361 0.91 MTNR1A (0.75) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL3815984 0.91 MTNR1A (0.75) MTNR1AMTNR1BTRPV1KMT2AMEN1
SCHEMBL14907359 0.90 MTNR1A (0.74) MTNR1AMTNR1BTRPV1HTR1A
SCHEMBL155073 0.89 TRPV1 (0.78) MTNR1AMTNR1BTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10583119-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2020-03-10 US disclosed
EP-2282735-B1 PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES SIGNUM BIOSCIENCES INC (US) 2019-01-16 EP disclosed
EP-2282735-B1 PP2A MODULATORS FOR TREATING ALZHEIMER, PARKINSON, DIABETES SIGNUM BIOSCIENCES INC (US) 2019-01-16 EP disclosed
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2017-09-21 US disclosed
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2017-09-21 US disclosed
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2017-09-21 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
US-9486441-B2 Compounds, compositions and methods for making the same SIGNUM BIOSCIENCES, INC. (US) 2016-11-08 US disclosed
EP-2282735-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME Signum Biosciences, Inc. (US) 2011-02-16 EP disclosed
WO-2009132051-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2009-10-29 WO disclosed
WO-2009132051-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME SIGNUM BIOSCIENCES, INC. (US) 2009-10-29 WO disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same PPP2CA, PPP4C, PPP6C MTNR1A 1889/4885MTNR1B 2090/4885TRPV1 4687/4885
US-20170266161-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME PPP2CA, PPP4C, PPP6C MTNR1A 1889/4885MTNR1B 2090/4885TRPV1 4687/4885
US-10583119-B2 Compounds, compositions and methods for making the same PPP2CA, PPP4C, PPP6C MTNR1A 1889/4885MTNR1B 2090/4885TRPV1 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.